Nuveen
OKUR

Nuveen’s OnKure Therapeutics OKUR Stock Holding History

Nuveen’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
+35,402
New +$152K ﹤0.01% 3675
2024
Q2 		– Sell
-1,804
Closed -$29.9K – 3430
2024
Q1 		$29.9K Hold
1,804
– – ﹤0.01% 3277
2023
Q4 		$28.9K Buy
1,804
+118
+7% +$7.35K ﹤0.01% 3312
2023
Q3 		$128K Hold
1,686
– – ﹤0.01% 3101
2023
Q2 		$111K Buy
+1,686
New +$136K ﹤0.01% 3154

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's OKUR Position: Q2 2026 in Review

Nuveen opened a new position in OnKure Therapeutics (OKUR) in Q2 2026: 35,402 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #3675 among its holdings. This is a return to the name: Nuveen previously reported a position in OKUR as recently as Q1 2024.

Nuveen first reported a position in OKUR in Q2 2023 and has held it in 5 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Nuveen held 35,402 shares of OnKure Therapeutics worth $161K as of Q2 2026.
  • OnKure Therapeutics was a new Nuveen position in Q2 2026.
  • OnKure Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3675 holding.
  • Nuveen first reported a position in OnKure Therapeutics in Q2 2023 and has held it in 5 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.